Boston (February 26, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing...
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the...
BOSTON, Feb. 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed...
Moncton, New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - February 25, 2025) - Breathe BioMedical, a company developing a breath analytics...
DELRAY BEACH, Fla., Feb. 25, 2025 /PRNewswire/ -- The global endoscopic ultrasonography market, valued at US$1.28 billion in 2023, is...
Mount Sinai and Kyabirwa Surgical Center Partnership Leverages Cutting-Edge Technology to Revolutionize Surgical Care in Uganda NEW YORK, Feb. 25,...
Global Biospecimen Leader to Unveil Transformative Tool for Oncology Studies HUNTSVILLE, Ala., Feb. 25, 2025 /PRNewswire/ -- Discovery Life Sciences...
300 million single cell atlas now accessible to the scientific community comprised of Vevo's Tahoe-100M, mapping 60,000 drug-patient interactions, and Arc's...
FREMONT, Calif., Feb. 25, 2025 /PRNewswire/ -- Ultima Genomics, Inc., developer of the UG100™ next-generation sequencing (NGS) platform, today announced expanded...
Silexion Completes Data Collection Phase in First-Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results...
Several subjects who received the highest dose in Phase 1 will also be included in Phase 2OCALA, Fla., Feb. 25,...
-- Lurie Cancer Center Completes Dosing of First Patient with LIXTE’s LB-100 in Combination with GSK’s Immunotherapy Dostarlimab -- PASADENA,...
February 24, 2025 Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use Biodexa plans to...
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the...
SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing...
Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric CancersNEW...
VANCOUVER, Washington, Feb. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab,...
Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today...
Patient enrollment set to begin at leading U.S. clinical trial sites, new drug product already deliveredTrial will advance stenoparib and...
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced...